Emergent Biosolutions (NYSE:EBS) and Sarepta Therapeutics (NASDAQ:SRPT) Head-To-Head Analysis

Emergent Biosolutions (NYSE:EBS – Get Free Report) and Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares Emergent Biosolutions and Sarepta Therapeutics”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Emergent Biosolutions $626.70 million 0.47 $52.60 million ($5.10) -1.14
Sarepta Therapeutics $2.20 billion 0.76 -$713.41 million ($1.37) -11.39

Emergent Biosolutions has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Emergent Biosolutions and Sarepta Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Emergent Biosolutions -40.16% -0.43% -0.15%
Sarepta Therapeutics -5.86% -0.20% -0.09%

Institutional & Insider Ownership

78.4% of Emergent Biosolutions shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Emergent Biosolutions has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Emergent Biosolutions and Sarepta Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Emergent Biosolutions 2 1 3 0 2.17
Sarepta Therapeutics 6 6 6 0 2.00

Emergent Biosolutions currently has a consensus price target of $10.00, indicating a potential upside of 72.41%. Sarepta Therapeutics has a consensus price target of $23.67, indicating a potential upside of 51.61%. Given Emergent Biosolutions’ stronger consensus rating and higher probable upside, analysts plainly believe Emergent Biosolutions is more favorable than Sarepta Therapeutics.

Summary

Sarepta Therapeutics beats Emergent Biosolutions on 9 of the 14 factors compared between the two stocks.

About Emergent Biosolutions

(Get Free Report)

Emergent BioSolutions is a biopharmaceutical company focused on products that address public health threats and medical emergencies. Its portfolio includes vaccines and treatments for infectious diseases, opioid overdose and other health risks, with customers that include governments and healthcare providers. Products associated with the company include BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; and NARCAN, a naloxone nasal spray used to reverse opioid overdose. Emergent also provides contract development and manufacturing services for pharmaceutical and biotechnology organizations.

About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.